Recent years have spurred the clinical trial industry to embrace innovative new solutions and technologies as a way to streamline processes and continue bringing trials to patients. However, the digital transformation started long before then. PSI CRO has consistently been a leader in applying sophisticated digital solutions to pivotal phase 2 and 3 clinical trials to optimize study modeling, budgeting, and operationalization, including developing our proprietary cloud-based suite of clinical trial planning tools, INTELIA™.
This forward-thinking approach also led to PSI’s early adoption of Robotic Process Automation (RPA) as a digital solution to standardize high-volume tasks and conduct them efficiently in an error-free manner. “While doing so, it builds quality control and compliance into the processes, cutting costs by 35 to 70%,” explained Doug Shannon, RPA Technology Lead at PSI CRO, in an interview with Labiotech.
PSI uses RPA to reduce processing time, human error rate, and the amount of routine work in several areas. For instance, automating the querying of abnormal laboratory values in EDC increased on time query processing by 100%. Other functions where RPA can support clinical trials include tasks that are heavy in documentation management, such as finance and accounting, supply chain, inventory management, and back-office processes like human resources and information technology services.
RPA offers several benefits for you as a sponsor, including:
- Freeing up PSI team members’ time to focus on your trial’s most critical tasks
- Capturing a sequential record of each step in every process, streamlining regulatory and drug safety data, and easing the burden of regulatory submissions preparation
- Supporting PSI’s therapeutic area subject matter experts as part of a cross-functional approach to clinical data collection, analysis, and management
To learn more about how PSI incorporates RPA and other industry-leading technologies into our global CRO services, contact us today.
For 25 years, we have built trusted relationships with biotech sponsors, with 90% of our customers being repeat and referral.
A sponsor of a pivotal Phase 3 prostate cancer study investigating a radiopharm product approached PSI for support based on our experience and established network of 300 global radiopharmaceutical sites.
Clinical trial sponsors working in oncology, hematology, IBD, infectious diseases, multiple sclerosis, and many rare diseases rely on PSI’s guidance and experience.
The PSI Advantage
For the sixth year in a row, PSI CRO has been named a CRO Leadership Award winner in the categories of Expertise, Quality, and Reliability in the Overall (combined Big and Small pharma) respondent group. The CRO Leadership Awards are presented by Life Sciences Leader and Clinical Leader based on research conducted by ISR Reports. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.